SARS-CoV-2 Antigens

In order to mitigate the rising need for in vitro diagnostics in the global COVID-19 scenario, InVivo now offers diverse SARS-CoV-2 proteins in large-scale quantities, which are suitable for the development of highly sensitive IVD kits. Using InVivo’s proprietary manufacturing platforms, different recombinant versions of the viral Spike protein have been transiently expressed in high yielding mammalian HEK cells. These include the two functional units, S1 and S2, and the Receptor Binding Domain (RBD) of the S1 subunit that directly engages with host cells via the human receptor Angiotensin Converting Enzyme 2 (ACE2).

To cater to larger demand of long-term bulk quantities in the gram scale, InVivo has also initiated development of several stable CHO cell lines. More information coming soon!

Schematic overview of the SARS-CoV-2 Spike (S) protein and its functional domains.

The S protein plays a crucial role in the infection process, and is therefore a great target for the development of diagnostic assays. It is comprised of two subunits: S1 and S2.

The S1 subunit (aa 1-681) enables binding of the virion to ACE2 receptor on the host cell membrane which initiates the infection. It contains an N-terminal signal peptide and the receptor-binding domain (RBD; aa 319-541) highlighted in grey.

The S2-subunit (aa 685-1273) contains a C-terminal transmembrane domain (TMD) and endodomain. It mediates the fusion of the virion with cellular membranes. The process of membrane fusion depends on S protein cleavage (Furin cleavage site, aa 682-685) leading to the activation of the S protein during infection.

SARS-CoV-2 Pipeline

Product-IDStructureDescriptionStatus
S1-RBD_CHORecombinant Spike protein receptor binding domain (aa 319-541) with C-terminal hexa-His-Tag, stably expressed in InVivo’s proprietary optimized CHO cell pools. 2-step purification via affinity chromatography and preparative SEC (polishing) to a purity  ≥​  90%.Available
S1-RBD_HEKRecombinant Spike protein receptor binding domain (aa 319-541) with C-terminal hexa-His-Tag, transiently expressed in InVivo´s proprietary optimized HEK-INV cells. 2-step purification via IMAC and preparative SEC (polishing) to a purity > 90%.

Product Information S1-RBD

Available
S1-Subunit_HEKRecombinant Spike protein S1-subunit (aa 14-681) with C-terminal hexa-His-Tag, transiently expressed in InVivo´s proprietary optimized HEK-INV cells. 2-step purification via IMAC and preparative SEC (polishing) to a purity > 90%.Available
S2-Subunit_HEKRecombinant Spike protein S2-subunit (aa 685-1213; excluding TMD and endodomain) with C-terminal hexa-His-Tag, transiently expressed in InVivo´s proprietary optimized HEK-INV cells. 2-step purification via IMAC and preparative SEC (polishing) to a purity > 90%.Available
Soluble Spike_HEKRecombinant soluble Spike protein (aa 14-1213), transiently expressed in InVivo´s proprietary optimized HEK-INV cells. The soluble Spike protein contains a mutated polybasic/ furin cleavage site (X), and mutations K986P / V987P (XX) for stabilization of the trimer. The C-terminal TMD and endodomain were replaced by a thrombin cleavage site, a trimerization site and a C-terminal hexa-His-Tag. 2-step purification via IMAC and preparative SEC (polishing) to a purity > 90%.Available

InVivo also offers custom solutions for the production of other Coronavirus antigens. If none of the products mentioned above are of your interest, please reach out to us and learn about production capacities and timelines for your protein of choice.

Contact Us

Invivo Biotech Services

Neuendorfstr. 24a
16761 Hennigsdorf
Germany

email_subscribe_callback

GDPR

6 + 7 =